{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T02:54:33Z","timestamp":1761706473677,"version":"build-2065373602"},"reference-count":20,"publisher":"Elsevier BV","issue":"38","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T00:00:00Z","timestamp":1724284800000},"content-version":"am","delay-in-days":387,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P51OD010425","R01AI141857","R03AI144143-01","U42OD011123"],"award-info":[{"award-number":["P51OD010425","R01AI141857","R03AI144143-01","U42OD011123"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.vaccine.2023.07.067","type":"journal-article","created":{"date-parts":[[2023,8,8]],"date-time":"2023-08-08T08:08:21Z","timestamp":1691482101000},"page":"5494-5498","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Preliminary studies on the immunogenicity of a prime-and-trap malaria vaccine in nonhuman primates"],"prefix":"10.1016","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8226-4354","authenticated-orcid":false,"given":"Melanie J.","family":"Shears","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felicia N.","family":"Watson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brad C.","family":"Stone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Cruz Talavera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chaitra","family":"Parthiban","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jokichi","family":"Matsubara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natasha","family":"KC","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B. Kim Lee","family":"Sim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen L.","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean C.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2023.07.067_b0005","unstructured":"WHO. World Malaria Report; 2022."},{"key":"10.1016\/j.vaccine.2023.07.067_b0010","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1080\/21645515.2019.1669415","article-title":"RTS, S\/AS01 vaccine (Mosquirix): an overview","volume":"16","author":"Laurens","year":"2020","journal-title":"Human Vacc Immunotherap"},{"key":"10.1016\/j.vaccine.2023.07.067_b0015","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(15)60721-8","article-title":"Clinical Trials Partnership. Efficacy and safety of RTS, S\/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial","volume":"386","author":"RTS","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2023.07.067_b0020","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.3389\/fimmu.2018.02748","article-title":"The development of whole sporozoite vaccines for Plasmodium falciparum malaria","volume":"9","author":"Itsara","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2023.07.067_b0025","doi-asserted-by":"crossref","first-page":"7452","DOI":"10.1016\/j.vaccine.2015.09.096","article-title":"Progress with Plasmodium falciparum sporozoite (PfSPZ)-based malaria vaccines","volume":"33","author":"Richie","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.07.067_b0030","doi-asserted-by":"crossref","first-page":"e31247","DOI":"10.1371\/journal.pone.0031247","article-title":"Protective CD8+ T lymphocytes in primates immunized with malaria sporozoites","volume":"7","author":"Weiss","year":"2012","journal-title":"PLoS One1"},{"key":"10.1016\/j.vaccine.2023.07.067_b0035","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/nm.4110","article-title":"Protection against malaria at 1 year and immune correlates following PfSPZ vaccination","volume":"22","author":"Ishizuka","year":"2016","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2023.07.067_b0040","doi-asserted-by":"crossref","first-page":"e89154","DOI":"10.1172\/jci.insight.89154","article-title":"Protection against Plasmodium falciparum malaria by PfSPZ Vaccine","volume":"2","author":"Epstein","year":"2017","journal-title":"JCI Insight"},{"key":"10.1016\/j.vaccine.2023.07.067_b0045","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/nature21060","article-title":"Sterile protection against human malaria by chemoattenuated PfSPZ vaccine","volume":"542","author":"Mordmuller","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2023.07.067_b0050","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1038\/s41467-021-22740-w","article-title":"Heterologous protection against malaria by a simple chemoattenuated PfSPZ vaccine regimen in a randomized trial","volume":"12","author":"Sulyok","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2023.07.067_b0055","doi-asserted-by":"crossref","first-page":"eabj3776","DOI":"10.1126\/scitranslmed.abj3776","article-title":"A randomized controlled trial showing safety and efficacy of a whole sporozoite vaccine against endemic malaria","volume":"14","author":"Sirima","year":"2022","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.vaccine.2023.07.067_b0060","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S1473-3099(21)00332-7","article-title":"Safety and efficacy of a three-dose regimen of Plasmodium falciparum sporozoite vaccine in adults during an intense malaria transmission season in Mali: a randomised, controlled phase 1 trial","volume":"22","author":"Sissoko","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2023.07.067_b0065","unstructured":"WHO. Malaria vaccines: preferred product characteristics and clinical development considerations; 2022."},{"key":"10.1016\/j.vaccine.2023.07.067_b0070","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.4049\/jimmunol.1800740","article-title":"Prime-and-trap malaria vaccination to generate protective CD8+ liver-resident memory T cells","volume":"201","author":"Olsen","year":"2018","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2023.07.067_b0075","doi-asserted-by":"crossref","DOI":"10.4269\/ajtmh.21-1084","article-title":"Cryopreserved sporozoites with and without the glycolipid adjuvant 7DW8-5 protect in prime-and-trap malaria vaccination","author":"Watson","year":"2022","journal-title":"American J Tropical Med Hygiene"},{"key":"10.1016\/j.vaccine.2023.07.067_b0080","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1186\/s12936-022-04261-z","article-title":"Efficient infection of non-human primates with purified, cryopreserved Plasmodium knowlesi sporozoites","volume":"21","author":"Chakravarty","year":"2022","journal-title":"Malar J"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2023.07.067_b0085","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1590\/S0074-02762011000900022","article-title":"Induction and maintenance of protective CD8+ T cells against malaria liver stages: implications for vaccine development","volume":"106","author":"Tse","year":"2011","journal-title":"Mem\u00f3rias do Instituto Oswaldo Cruz"},{"key":"10.1016\/j.vaccine.2023.07.067_b0090","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1186\/s12936-020-03385-4","article-title":"Quantification of Plasmodium knowlesi versus Plasmodium falciparum in the rhesus liver: implications for malaria vaccine studies in rhesus models","volume":"19","author":"Shears","year":"2020","journal-title":"Malar J"},{"key":"10.1016\/j.vaccine.2023.07.067_b0095","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1126\/science.2409595","article-title":"Rationale for development of a synthetic vaccine against Plasmodium falciparum malaria","volume":"228","author":"Zavala","year":"1985","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2023.07.067_b0100","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.4049\/jimmunol.1003411","article-title":"Cutting edge: selective role of ubiquitin in MHC class I antigen presentation","volume":"186","author":"Huang","year":"2011","journal-title":"J Immunol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23009131?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23009131?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:30:07Z","timestamp":1759404607000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X23009131"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":20,"journal-issue":{"issue":"38","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S0264410X23009131"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.07.067","relation":{},"ISSN":["0264-410X"],"issn-type":[{"type":"print","value":"0264-410X"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preliminary studies on the immunogenicity of a prime-and-trap malaria vaccine in nonhuman primates","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.07.067","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}